BeOne Medicines AG (BVMF:B1ME34)

Market Cap	191.22B
Revenue (ttm)	24.86B
Net Income (ttm)	-967.93M
Shares Out	n/a
EPS (ttm)	-9.06
PE Ratio	n/a
Forward PE	74.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Average Volume	30
Open	70.56
Previous Close	67.55
Day's Range	70.56 - 70.56
52-Week Range	41.50 - 70.56
Beta	n/a
RSI	75.51
Earnings Date	Aug 29, 2025

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: B1ME34

Financial Performance

In 2024, BeOne Medicines AG's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD